Please login to the form below

Not currently logged in
Email:
Password:

HAE

This page shows the latest HAE news and features for those working in and with pharma, biotech and healthcare.

EMA starts rapid review of Shire’s HAE antibody

EMA starts rapid review of Shire’s HAE antibody

two weeks resulted in an 87% reduction in the mean frequency of HAE attacks overall, according to Shire. ... Other approved treatments for HAE include CSL Behring’s Berinert and Pharming’s Ruconest.

Latest news

  • Shire completes $32bn Baxalta merger Shire completes $32bn Baxalta merger

    The pipeline will focus on therapy areas including haematology, immunology, neuroscience, lysosmal storage disorders, gastrointestinal/endocrine and disease and hereditary angioedema (HAE), and brings Baxalta's haemophilia franchise into the fold.

  • Baxalta agrees to $32bn Shire takeover Baxalta agrees to $32bn Shire takeover

    disease therapies across haematology, immunology, neuroscience, lysosomal storage disorders, gastrointestinal/endocrine and disease and hereditary angioedema (HAE). ... drugs such as its HAE therapy Cinryze (C1 esterase inhibitor) and Natpara

  • Shire deal with Baxalta predicted this week Shire deal with Baxalta predicted this week

    HAE) therapy DX-2930 - and a $5.2bn purchase of NPS Pharma which gave it control of Natpara (recombinant parathyroid hormone) for hypoparathyroidism.

  • FDA grants fast track designation to Shire’s Cinryze FDA grants fast track designation to Shire’s Cinryze

    Cinryze is currently only approved for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE) and is used to prevent swelling or painful episodes. ... HAE is characterised by recurrent sudden

  • Shire launches rare disease website Shire launches rare disease website

    Shire launches rare disease website. Hereditary angioedema sitesupports its Me, Not HAE campaign. ... Shire has launched an awareness website for hereditary angioedema (HAE) as part of its Me, Not HAE campaign.

More from news
Approximately 2 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • A rare talent A rare talent

    and HAE.”.

  • Deal Watch November 2015 Deal Watch November 2015

    Given that Shire's Cinryze is already approved in HAE, It will be interesting to see what the regulators say on the anti-competition front. ... 160, 000. Dyax Corporation. Shire. Acquisition - company. Includes KALBITOR marketed for acute attacks of HAE

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics